Development of neuropeptide drugs that cross the blood-brain barrier

Richard D. Egleton, Thomas P. Davis

Research output: Contribution to journalArticle

110 Scopus citations

Abstract

In recent years, there have been several important advancements in the development of neuropeptide therapeutics. Nevertheless, the targeting of peptide drugs to the CNS remains a formidable obstacle. Delivery of peptide drugs is limited by their poor bioavailability to the brain due to low metabolic stability, high clearance by the liver, and the presence of the blood brain barrier (BBB). Multiple strategies have been devised in an attempt to improve peptide drug delivery to the brain, with variable results. In this review, we discuss several of the strategies that have been used to improve both bioavailability and BBB transport, with an emphasis on antibody based vector delivery, useful for large peptides/small proteins, and glycosylation, useful for small peptides. Further development of these delivery methods may finally enable peptide drugs to be useful for the treatment of neurological disease states.

Original languageEnglish (US)
Pages (from-to)44-53
Number of pages10
JournalNeuroRx
Volume2
Issue number1
DOIs
StatePublished - Jan 2005

Keywords

  • Antibody based vectors
  • Blood brain barrier peptide transport
  • Glycopeptides
  • Transferrin receptor

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Development of neuropeptide drugs that cross the blood-brain barrier'. Together they form a unique fingerprint.

  • Cite this